Daniel Bradbury - Feb 5, 2024 Form 4 Insider Report for CASTLE BIOSCIENCES INC (CSTL)

Role
Director
Signature
/s/ Frank Stokes, Attorney-in-fact
Stock symbol
CSTL
Transactions as of
Feb 5, 2024
Transactions value $
-$493,818
Form type
4
Date filed
2/7/2024, 04:19 PM
Previous filing
Jan 8, 2024
Next filing
Feb 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSTL Common Stock Sale -$62.6K -2.75K -4.25% $22.74 61.9K Feb 5, 2024 By LLC F1, F2, F3
transaction CSTL Common Stock Sale -$67.4K -2.96K -7.08% $22.74 38.9K Feb 5, 2024 By Daniel Bradbury Irrecovable Descendant's Trust F1, F2, F4
transaction CSTL Common Stock Sale -$67.4K -2.96K -7.08% $22.74 38.9K Feb 5, 2024 By Annette Bradbury Irrecovable Descendant's Trust F1, F2, F5
transaction CSTL Common Stock Sale -$20.2K -863 -1.39% $23.42 61.1K Feb 5, 2024 By LLC F1, F3, F6
transaction CSTL Common Stock Sale -$21.8K -930 -2.39% $23.42 37.9K Feb 5, 2024 By Daniel Bradbury Irrecovable Descendant's Trust F1, F4, F6
transaction CSTL Common Stock Sale -$21.8K -931 -2.39% $23.42 38K Feb 5, 2024 By Annette Bradbury Irrecovable Descendant's Trust F1, F5, F6
transaction CSTL Common Stock Sale -$73.7K -3.12K -5.11% $23.63 58K Feb 6, 2024 By LLC F1, F3, F7
transaction CSTL Common Stock Sale -$79.4K -3.36K -8.86% $23.63 34.6K Feb 6, 2024 By Daniel Bradbury Irrecovable Descendant's Trust F1, F4, F7
transaction CSTL Common Stock Sale -$79.5K -3.36K -8.86% $23.63 34.6K Feb 6, 2024 By Annette Bradbury Irrecovable Descendant's Trust F1, F5, F7
holding CSTL Common Stock 4.66K Feb 5, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC, The Daniel M. Bradbury Irrevocable Descendants' Trust and The Annette E. Bradbury Irrevocable Descendants' Trust on August 22, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $22.33 to $23.32, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.
F4 Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
F5 Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries.
F6 This transaction was executed in multiple trades at prices ranging from $23.33 to $23.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $23.22 to $23.95, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.